IL28B genomic-based treatment paradigms for patients with chronic hepatitis C infection: the future of personalized HCV therapies.
about
Natural history and clinical response: "it's the virus, stupid, or is it the host?"Benefit of Treatment Individualization in Patients with Chronic Hepatitis C Receiving Peginterferon Alfa-2a and Ribavirin in a Large Noninterventional Cohort StudySequence analysis of the IL28A/IL28B inverted gene duplication that contains polymorphisms associated with treatment response in hepatitis C patientsSerum ferritin levels are associated with a distinct phenotype of chronic hepatitis C poorly responding to pegylated interferon-alpha and ribavirin therapy.IL28B polymorphisms and clinical implications for hepatitis C virus infection in UzbekistanThe cost-effectiveness of improved hepatitis C virus therapies in HIV/hepatitis C virus coinfected patients.Bench-to-bedside review: future novel diagnostics for sepsis - a systems biology approach.A genetic validation study reveals a role of vitamin D metabolism in the response to interferon-alfa-based therapy of chronic hepatitis C.Meta-analysis: implications of interleukin-28B polymorphisms in spontaneous and treatment-related clearance for patients with hepatitis C.IL28B and IL10R -1087 polymorphisms are protective for chronic genotype 1 HCV infection and predictors of response to interferon-based therapy in an East-Central European cohortCharacteristics and PD-1 expression of peripheral CD4+CD127loCD25hiFoxP3+ Treg cells in chronic HCV infected-patients.Demographics, clinical characteristics, IFNL3- and IFNL4- polymorphisms in a cohort of hepatitis C patients from Puerto Rico.IL28B genotype predicts response to chronic hepatitis C triple therapy with telaprevir or boceprevir in treatment naïve and treatment-experienced patients other than prior partial- and null-responders.Current standards in the treatment of chronic hepatitis C.IL28B polymorphism as a predictor of antiviral response in chronic hepatitis C.Association of Single-Nucleotide Polymorphisms in IL28B, but Not TNF-α, With Severity of Disease Caused by Andes VirusIL28B polymorphisms predict the virological response to standard therapy in patients with chronic hepatitis C virus genotype 4 infection.Pharmacogenomics in clinical practice and drug development.Role of viral and host factors in interferon based therapy of hepatitis C virus infectionTolerability and efficacy of pegylated consensus interferon-α in the treatment of chronic hepatitis C.Interleukin 28B Polymorphisms and Hepatitis C-Translating the Association into Clinical Decision MakingIndividualization of chronic hepatitis C treatment according to the host characteristics.A new standard of care for the treatment of chronic HCV infection.Translating pharmacogenetics into clinical practice: interleukin (IL)28B and inosine triphosphatase (ITPA) polymophisms in hepatitis C virus (HCV) infection.Systematic review: epidemiology of hepatitis C genotype 6 and its management.Infections and the liver.Response-guided and -unguided treatment of chronic hepatitis C.Treating hepatitis C: current standard of care and emerging direct-acting antiviral agents.Genomic variation-guided management in chronic hepatitis C.Systematic review: Asian patients with chronic hepatitis C infection.IL28B polymorphisms associated with therapy response in Chilean chronic hepatitis C patients.Association between interferon use and reduced metabolic and vascular complications among patients with hepatitis C.Novel biosensor-based microarray assay for detecting rs8099917 and rs12979860 genotypes.The genotype CC of IL-28B SNP rs12979860 is significantly associated with a sustained virological response in chronic HCV-infected Pakistani patients.Pharmacogenetics in Ghana.Prevalence of IL-28B and ITPA genotypes in Chinese Han population infected persistently with hepatitis C virus genotype 6 or HCV-1.Sustained virological response after 4 weeks of telaprevir, peginterferon, and ribavirin in an Asian patient with genotype 1 chronic hepatitis C and IL28B genotype CC.Meta-analysis: IL28B polymorphisms predict sustained viral response in HCV patients treated with pegylated interferon-α and ribavirin.Assessing the cost utility of response-guided therapy in patients with chronic hepatitis C genotype 1 in the UK using the MONARCH model.The Effects of IL-28B and ITPA polymorphisms on treatment of hepatitis C virus genotype 6.
P2860
Q26824094-9235FE79-6C25-4F8C-B56F-7D578D7101C1Q28546936-DCAA8ABA-F362-481B-8DC4-2874430EBE37Q28732905-02CBE247-7E7A-40C9-81C2-A7B4FB126C51Q29417108-B24D7E4C-0CBA-4FB3-9F88-0688341FC2F2Q31154491-F77E36B6-5DC2-4698-BC9D-6DE826354C2CQ33710740-5D11B492-AEA0-4035-925B-9BC49F4AFE61Q33754619-18A848FF-CC0A-4856-93F2-AA92837EEF0CQ34341819-09847DA4-B336-4615-978F-6C9C7C9E8871Q34539324-EBE7D5BE-1857-4A44-819F-3D2B455B3C47Q35084548-E49E6A79-F0AD-47A0-9D39-63343AD3BB04Q35085469-C5B4724B-2E3C-4C31-AF88-51A24647EEBEQ35112286-51FF7CFA-54F9-452C-87FB-4BF687E59A97Q35855775-7C720769-AFED-4273-88C0-C1A9F75EB722Q35999496-52142236-0E20-4950-84E7-B0FBF52556EFQ36248186-B2827CB5-FCA6-4E0E-AE23-DB104B749C77Q36311463-1A05DD38-87AC-4652-B139-349EB76317CCQ36963985-44F6DEF8-56A7-4146-A33D-9B10C4D98F77Q37284234-9CF61877-A1FE-4D11-B3E4-16DB4AF62DC8Q37362240-249122EC-20DA-4DCF-AFD0-71D0C7DCFF8EQ37593837-5468AFAD-DA2E-4942-90C9-566350E0ED39Q37613481-6851469D-AC7B-4D9B-818F-200D2B891E77Q37654502-4308F504-C09F-4286-9952-629DCAB3E3C3Q37862076-EA1D89BB-755F-40E7-BB6B-BA615A1D879CQ37879701-8B73D36A-3490-42AB-AB23-DF85DBB66235Q37882006-3AD74407-B489-457E-A44F-CA6024673D5FQ37898411-81494D51-B17A-42CA-9939-3B54D1CDB847Q37972765-C15DD41D-01DE-4730-AFEF-6025EE100D32Q38016958-5ECC9288-2D4E-423E-A2A1-46FA4EDC31D0Q38038693-BDC264CB-D6F2-47BA-BF8B-F41CB40EEA07Q38096012-9C2123A9-22ED-42C4-A0C7-8A8F37758C1BQ38560952-A5B81E26-FD4F-4F30-B39C-C7E2ECF8B930Q39146830-3766A065-2335-4FA4-AEB9-103E571CBEC2Q40077714-800215A4-CA7F-4045-B3DB-9714C2F370B0Q41467901-51B7A046-352C-46BD-9EC3-6A97DEE37F20Q42201096-281AEE5C-F12C-49DD-857D-33D4BB62F9D8Q42252312-D065942B-7B30-4CFB-8603-1F269848000EQ42263477-1032CF83-306B-4597-9D25-8ACEC8FFF480Q42980402-4277BC3C-74A6-4308-AF94-30D42FDB6048Q42988428-97A93A85-D76D-49F6-9640-608550BE81DBQ43036492-C64AE0D7-2BFF-4100-869E-BA6CA119DAC5
P2860
IL28B genomic-based treatment paradigms for patients with chronic hepatitis C infection: the future of personalized HCV therapies.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 05 October 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
IL28B genomic-based treatment ...... of personalized HCV therapies.
@en
IL28B genomic-based treatment ...... of personalized HCV therapies.
@nl
type
label
IL28B genomic-based treatment ...... of personalized HCV therapies.
@en
IL28B genomic-based treatment ...... of personalized HCV therapies.
@nl
prefLabel
IL28B genomic-based treatment ...... of personalized HCV therapies.
@en
IL28B genomic-based treatment ...... of personalized HCV therapies.
@nl
P2093
P2860
P356
P1476
IL28B genomic-based treatment ...... of personalized HCV therapies.
@en
P2093
Alex J Thompson
John G McHutchison
Paul J Clark
P2860
P356
10.1038/AJG.2010.370
P407
P577
2010-10-05T00:00:00Z